Viatris Inc. Q1 2026 Earnings Recap

Viatris shares rose 7.6% following Q1 results, driven primarily by solid execution in Greater China and progress on key product approvals that ease growth concerns. The market rewarded the company's pipeline milestones and commercial momentum despite no major changes to guidance.

Key Takeaways

• Reported Q1 revenues of $3.5 billion, up 3% year-over-year, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59 per share.
• Strong commercial execution in Greater China significantly contributed to revenue growth; Japan showed improving momentum with the EFFEXOR launch for generalized anxiety disorder.
• Regulatory progress remains on track with one product approved this quarter and five additional decisions expected in the second half, including the contraceptive patch XULANE LO and fast-acting meloxicam.
• Management emphasized disciplined capital allocation, continuing to balance shareholder returns with investments in growth and pipeline development.
• Strategic initiatives to optimize costs and improve operational efficiency are progressing as planned, supporting margin sustainability.